X4 Pharmaceuticals (XFOR) Assets Average (2018 - 2025)

X4 Pharmaceuticals' Assets Average history runs 8 years deep, the most recent figure standing at $227.0 million for Q4 2025.

• Quarterly Assets Average rose 39.86% year-over-year to $227.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $227.0 million (up 39.86% YoY) and the FY2025 annual result came in at $218.5 million, up 48.76% from the prior year.
• Assets Average was $227.0 million for Q4 2025 at X4 Pharmaceuticals, up from $134.4 million in the prior quarter.
• Across five years, Assets Average topped out at $227.0 million in Q4 2025 and bottomed at $90.3 million in Q2 2022.
• A 5-year average of $143.1 million and a median of $139.1 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average plunged 40.32% — and 2023, when it surged 78.32%.
• X4 Pharmaceuticals' Assets Average stood at $118.8 million in 2021, then increased by 13.17% to $134.5 million in 2022, then gained by 19.17% to $160.3 million in 2023, then advanced by 1.27% to $162.3 million in 2024, then surged by 39.86% to $227.0 million in 2025.
• Business Quant data shows XFOR's Assets Average at $227.0 million in Q4 2025, $134.4 million in Q3 2025, and $117.6 million in Q2 2025.